{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:29:53Z","timestamp":1785886193026,"version":"3.56.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Japan Research Committee of the Ministry of Health, Labour and Welfare for Intractable Vasculitis from the Ministry of Health, Labour and Welfare of Japan","award":["23FC1019"],"award-info":[{"award-number":["23FC1019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine real-world clinical practices in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) across Japan and evaluate concordance with national treatment guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional, web-based survey was conducted between 14 and 19 February 2024. Physicians from rheumatology, pulmonology, and neurology departments who had treated EGPA within the past 24\u00a0months were invited to complete a 17-item questionnaire. The survey assessed actual prescribing behaviour, future treatment preferences, responses to two clinical scenarios, and the frequency of guideline use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 220 respondents (110 rheumatologists, 55 neurologists, and 55 pulmonologists), cyclophosphamide (77.3%) and mepolizumab (73.2%) were frequently used with glucocorticoids (GCs) for remission induction. GC monotherapy was the most commonly selected option overall (31.4%), but its use decreased to 14.8% for severe cases. GC\u2009+\u2009mepolizumab was the most frequently selected regimen for both maintenance and relapse. Responses to clinical scenarios revealed partial divergence from guideline-based recommendations, particularly regarding the limited use of immunosuppressants and the preferential use of mepolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identified a modest but clear evidence\u2013practice gap in EGPA management in Japan. Broader dissemination of updated guidelines and enhanced interdisciplinary collaboration may help align clinical practice with evidence-based standards and improve patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf064","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:19:52Z","timestamp":1751872792000},"page":"68-76","source":"Crossref","is-referenced-by-count":1,"title":["Concordance between treatment guideline and daily practice in the management of eosinophilic granulomatosis with polyangiitis: a cross-sectional web-questionnaire survey"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-5296","authenticated-orcid":false,"given":"Ryu","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshia","family":"Miyawaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine , Dentistry and Pharmaceutical Sciences, Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University , Saga ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Bando","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025122205121954500_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025122205121954500_ref2","doi-asserted-by":"crossref","first-page":"627776","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025122205121954500_ref3","doi-asserted-by":"crossref","first-page":"iii84","DOI":"10.1093\/rheumatology\/kez570","article-title":"Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management","volume":"59","author":"Trivioli","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025122205121954500_ref4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"2025122205121954500_ref5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12185996","article-title":"Eosinophilic granulomatosis with polyangiitis: latest findings and updated treatment recommendations","volume":"12","author":"Watanabe","year":"2023","journal-title":"J Clin Med"},{"key":"2025122205121954500_ref6","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1136\/ard-2024-225606","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025122205121954500_ref7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025122205121954500_ref8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2025122205121954500_ref9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/mr\/roae044","article-title":"Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a multicentre REVEAL cohort study","volume":"35","author":"Shiomi","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025122205121954500_ref10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-022-02845-3","article-title":"Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study","volume":"24","author":"Ueno","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025122205121954500_ref11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2045-7022-4-38","article-title":"High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis","volume":"4","author":"Tsurikisawa","year":"2014","journal-title":"Clin Transl Allergy"},{"key":"2025122205121954500_ref12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00415-014-7618-y","article-title":"Research group for IfECSSiJ. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial","volume":"262","author":"Koike","year":"2015","journal-title":"J Neurol"},{"key":"2025122205121954500_ref13","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/mr\/road104","article-title":"Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: real-world database analysis","volume":"34","author":"Sada","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025122205121954500_ref14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/mr\/road081","article-title":"Clinical practice guidelines of the Japan research Committee of the Ministry of Health, Labour, and Welfare for intractable vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: the 2023 update - secondary publication","volume":"34","author":"Sada","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025122205121954500_ref15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/mr\/roac114","article-title":"Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan research Committee of the Ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis","volume":"33","author":"Watanabe","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025122205121954500_ref16","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/mr\/roae034","article-title":"Real-world clinical decisions of physicians in the management of Takayasu arteritis and giant cell arteritis in Japan: a cross-sectional web questionnaire survey","volume":"34","author":"Abe","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025122205121954500_ref17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/mr\/roac118","article-title":"Concordance between practice and published evidence in the management of ANCA-associated vasculitis in Japan: a cross-sectional web-questionnaire survey","volume":"33","author":"Miyawaki","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025122205121954500_ref18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(03)14546-1","article-title":"From best evidence to best practice: effective implementation of change in patients' care","volume":"362","author":"Grol","year":"2003","journal-title":"Lancet."},{"key":"2025122205121954500_ref19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1346-8138.12971","article-title":"Transient improvement of urticaria induces poor adherence as assessed by Morisky medication adherence Scale-8","volume":"42","author":"Kaneko","year":"2015","journal-title":"J Dermatol"},{"key":"2025122205121954500_ref20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025122205121954500_ref21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025122205121954500_ref22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdent.2020.103469","article-title":"Evidence-practice gap in minimal intervention dentistry: findings from a dental practice-based research network","volume":"102","author":"Kakudate","year":"2020","journal-title":"J Dent"},{"key":"2025122205121954500_ref23","doi-asserted-by":"crossref","first-page":"1457202","DOI":"10.3389\/fimmu.2024.1457202","article-title":"Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study","volume":"15","author":"Shiomi","year":"2024","journal-title":"Front Immunol"},{"key":"2025122205121954500_ref24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/mrcr\/rxac017","article-title":"A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab","volume":"6","author":"Ueno","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025122205121954500_ref25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis study group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"2025122205121954500_ref26","doi-asserted-by":"crossref","DOI":"10.1093\/mr\/roaf026","article-title":"Relapses and treatment status in elderly and non-elderly patients with eosinophilic granulomatosis with polyangiitis: a retrospective observational study using Japanese nationwide claims data","author":"Taniguchi","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2025122205121954500_ref27","doi-asserted-by":"crossref","DOI":"10.3390\/biom15040544","article-title":"Comparative insights on IL-5 targeting with mepolizumab and Benralizumab: enhancing EGPA treatment strategies","volume":"15","author":"Shiomi","year":"2025","journal-title":"Biomolecules."},{"key":"2025122205121954500_ref28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf064\/63702171\/roaf064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/1\/68\/63702171\/roaf064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/1\/68\/63702171\/roaf064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:12:29Z","timestamp":1766398349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/1\/68\/8193396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf064","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,7,8]]}}}